Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Alzheimer Disease, Date of authorisation: 21/04/2013, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996cc ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/12/2009, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1930425 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Axura, memantine, Alzheimer Disease, Date of authorisation: 17/05/2002, Revision: 25, Status: Authorised

Case Medical Research ◽

10.31525/cmr-210d408 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Memantine Accord, memantine, Alzheimer Disease, Date of authorisation: 03/12/2013, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5014c0 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Alzheimer Disease, Date of authorisation: 21/04/2013, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-17cd5ce ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging,Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 14, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b07ad1 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Radionuclide Imaging ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-587204 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-559118 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 35, Status: Authorised

Case Medical Research ◽

10.31525/cmr-559115 ◽

2018 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): DaTSCAN, ioflupane (123l), Tomography, Emission-Computed, Single-Photon,Lewy Body Disease,Parkinson Disease,Alzheimer Disease, Date of authorisation: 27/07/2000, Revision: 21, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1891668 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Lewy Body ◽

Single Photon ◽

Lewy Body Disease ◽

Assessment Report ◽

Emission Computed ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Memantine Merz, memantine hydrochloride, Alzheimer Disease, Date of authorisation: 22/11/2012, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-210d406 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text